FDA accepts Saol Therapeutics' resubmission of SL1009 (DCA) for PDCD, setting a PDUFA date of Dec 30, 2026
Executive summary: On July 28, 2026, the FDA announced it had accepted Saol Therapeutics’ resubmission of SL1009 (dichloroacetate) for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), classifying it as a complete Class II response. The acceptance triggers a formal review period with a PDUFA date set for Dec 30, 2026, bringing the first potential therapy for a lethal mitochondrial disease closer to market.
Who is involved: Saol Therapeutics (sponsor), the U.S. Food and Drug Administration (reviewing agency), and patients with PDCD.
Likely next: Saol will continue to work with the FDA through the review process, aiming for an approval decision by the PDUFA date of Dec 30, 2026.
The FDA’s acceptance of the resubmission as a complete Class II response means the agency will review SL1009 under a standard 10‑month clock, with a decision expected by Dec 30, 2026. SL1009 targets pyruvate dehydrogenase complex deficiency, a rare and fatal mitochondrial disease lacking approved therapies. This milestone advances Saol’s lead candidate toward potential approval, though the long timeline reflects the disease’s complexity and the FDA’s cautious stance.
Timeline
- — Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026 (PR Newswire)
Analysis — what this means
Likely next events
- FDA PDUFA decision on SL1009 expected Dec 30, 2026
Sectors affected
- PDCD therapy
- mitochondrial disease drug development
- rare disease therapeutics
Regulatory implications
- FDA’s acceptance of a Class II resubmission starts a 10‑month review clock under the FD&C Act, leading to the Dec 30, 2026 PDUFA date
- If approved, SL1009 would qualify for orphan drug exclusivity for PDCD
Historical parallels
- FDA issued a Complete Response Letter (CRL) for SL1009 on Aug 27, 2025, prompting the current resubmission
Key entities
Sources
- Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026 — PR Newswire
Related cases
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
- FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy